雅培(ABT.US)获FDA新冠抗体测试紧急使用授权
© Reuters. 雅培(ABT.US)获FDA新冠抗体测试紧急使用授权
智通财经APP获悉，雅培(ABT.US)于今日(10月12日)表示，该公司已收到美国食品和药物管理局（FDA）的紧急使用授权，以进行检测新冠病毒抗体。
该项测试使用了雅培的Architect和Alinity平台检测IgM抗体，可用于确定某人最近或以前是否感染了过SARS-CoV-2。
雅培表示，这项测试是对公司已经开发的IgG抗体测试的补充。IgG检测适合于检测长期感染的可能性，而IgM检测则适用于检测近期感染的可能性。
10月12日(周一)美股盘初，截至北京时间21：48，该股上涨0.63%，报110.31美元。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.